reports
Adecco Group AG: 1 director
A director at Adecco Group AG bought 4,000 shares at 20.900CHF and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Heidelberg Materials AG: 1 director
A director at Heidelberg Materials AG bought 125 shares at 187.450EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
- Chaima Ferrandon
- Sven Edelfelt
GET GETLINK SE
VIE VEOLIA ENVIRONNEMENT SA
RR. ROLLS-ROYCE HOLDINGS PLC
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
BVI BUREAU VERITAS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
PUM PUMA SE
SK SEB SA
FGR EIFFAGE SA
EBS ERSTE GROUP BANK AG
EN BOUYGUES SA
LSEG LONDON STOCK EXCHANGE GROUP PLC
EOAN E.ON SE
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
PZU POWSZECHNY ZAKLAD UBEZPIECZEN SPOLKA AKCYJNA
HEI HEIDELBERGCEMENT AG
UCB UCB S.A.
DTE DEUTSCHE TELEKOM AG
WPP WPP PLC
EDW EDP RENOVAVEIS SA
KGX KION GROUP AG
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
PRY PRYSMIAN S.P.A.
IBE IBERDROLA SA
PIRC PIRELLI & C. S.P.A.
ARGX ARGEN-X SE
HAG HENSOLDT AG
STLA STELLANTIS N.V.
CTPNV CTP NV
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
FER FERROVIAL SA
SYENS SYENSQO
- Chaima Ferrandon
- Sven Edelfelt
GET GETLINK SE
VIE VEOLIA ENVIRONNEMENT SA
RR. ROLLS-ROYCE HOLDINGS PLC
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
BVI BUREAU VERITAS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
PUM PUMA SE
SK SEB SA
FGR EIFFAGE SA
EN BOUYGUES SA
LSEG LONDON STOCK EXCHANGE GROUP PLC
EOAN E.ON SE
REE RED ELECTRICA CORP. SA
ENI ENI S.P.A.
PZU POWSZECHNY ZAKLAD UBEZPIECZEN SPOLKA AKCYJNA
HEI HEIDELBERGCEMENT AG
UCB UCB S.A.
DTE DEUTSCHE TELEKOM AG
WPP WPP PLC
EDW EDP RENOVAVEIS SA
KGX KION GROUP AG
ACS ACTIVIDADES DE CONSTRUCCION Y SERVICIOS SA
PRY PRYSMIAN S.P.A.
IBE IBERDROLA SA
PIRC PIRELLI & C. S.P.A.
ARGX ARGEN-X SE
HAG HENSOLDT AG
STLA STELLANTIS N.V.
CTPNV CTP NV
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
FER FERROVIAL SA
SYENS SYENSQO
- Chaima Ferrandon
- Sven Edelfelt
- Chaima Ferrandon
- Sven Edelfelt
- Konrad Zomer
BVI BUREAU VERITAS SA
DGE DIAGEO PLC
SK SEB SA
ADEN ADECCO GROUP AG
AGS AGEAS SA/NV
NESN NESTLE S.A.
WKL WOLTERS KLUWER NV
EOAN E.ON SE
ELE ENDESA S.A.
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
EDW EDP RENOVAVEIS SA
MONC MONCLER SPA
TIT TELECOM ITALIA S.P.A.
IBE IBERDROLA SA
LDO LEONARDO SPA
ALC ALCON INC.
BEAN BELIMO HOLDING AG
SDZ SANDOZ GROUP AG
AENA AENA S.M.E. SA
- Konrad Zomer
BVI BUREAU VERITAS SA
DGE DIAGEO PLC
SK SEB SA
ADEN ADECCO GROUP AG
AGS AGEAS SA/NV
NESN NESTLE S.A.
WKL WOLTERS KLUWER NV
EOAN E.ON SE
ELE ENDESA S.A.
FRE FRESENIUS SE & CO. KGAA
HEI HEIDELBERGCEMENT AG
PKN POLSKI KONCERN NAFTOWY ORLEN S.A.
EDW EDP RENOVAVEIS SA
MONC MONCLER SPA
TIT TELECOM ITALIA S.P.A.
IBE IBERDROLA SA
LDO LEONARDO SPA
ALC ALCON INC.
BEAN BELIMO HOLDING AG
SDZ SANDOZ GROUP AG
AENA AENA S.M.E. SA
- Chaima Ferrandon
- Sven Edelfelt
- Chaima Ferrandon
- Sven Edelfelt
- Konrad Zomer
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as t...
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placeboAFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring ...
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé au...
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par une étude de phase 3 démontrant que Dupixent a réduit de manière significative les signes et symptômes nasaux ainsi que le recours aux corticostéroïdes systémiques ou à la chirurgie par rapport au placeboL’AFRS e...
- Adrian Pehl
EO FAURECIA SA
ZIL2 ELRINGKLINGER AG
F3C SFC ENERGY AG
OERL OC OERLIKON CORPORATION AG
ELG ELMOS SEMICONDUCTOR SE
SOLB SOLVAY SA
NEX NEXANS SA
UTG UNITE GROUP PLC
INH INDUS HOLDING AG
WIE WIENERBERGER AG
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
VASTB VASTNED RETAIL BELGIUM NV
DOKA DORMAKABA HOLDING AG
ALR ALIOR BANK SA
GLPG GALAPAGOS NV
ALM ALMIRALL SA
MVC METROVACESA SA
THEON THEON INTERNATIONAL PLC
ORP ORPEA
EXENS EXOSENS
FERGR FERRARI GROUP PUBLIC LIMITED COMPANY
- Adrian Pehl
EO FAURECIA SA
ZIL2 ELRINGKLINGER AG
F3C SFC ENERGY AG
OERL OC OERLIKON CORPORATION AG
ELG ELMOS SEMICONDUCTOR SE
SOLB SOLVAY SA
NEX NEXANS SA
UTG UNITE GROUP PLC
INH INDUS HOLDING AG
WIE WIENERBERGER AG
VLK VAN LANSCHOT KEMPEN NV CERT. OF SHS
VASTB VASTNED RETAIL BELGIUM NV
DOKA DORMAKABA HOLDING AG
ALR ALIOR BANK SA
GLPG GALAPAGOS NV
ALM ALMIRALL SA
MVC METROVACESA SA
THEON THEON INTERNATIONAL PLC
ORP ORPEA
EXENS EXOSENS
FERGR FERRARI GROUP PUBLIC LIMITED COMPANY
- ING Helpdesk
Benelux Morning Notes
CFE: Preview: underlying 2026 margin to improve / DEME: Preview: strong 2025, eyes on 2026 outlook / JDE Peet's: Acquisition by KDP expected to close in 2Q26 / Solvay: 2025 ends with strong FCF; 2026F und. EBITDA guidance slightly below, supported by one-off / UCB: Peer Moonlake investor day / Vastned: Beat on bottom line with operational metrics accelerating, but outlook remains weak
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Wim Hoste
Solvay FIRST LOOK: 4Q25 soft but in line with consensus, cautious FY26...
4Q uEBITDA dropped by c. 30% organ. and was in line with CSS and c. 5% below our forecast. FY26 uEBITDA guidance of € 770-850m represents a 4-13% y/y decline and is at midpoint c. 2% below consensus and 7% below our forecast. The dividend policy (stable to increasing from a € 2.43 base) looks increasingly generous as the FY26 FCF will not be enough to service the dividend and will hence push up leverage from the current 1.8x. Despite the attractive dividend yield (c 9%), the tough market conditi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.